Inve India ▾

Unichem Laboratories share price & results

Unichem Laboratories Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q3 FY17
Ownership as of
Sept 2026

Ipca Laboratories subsidiary; manufactures APIs and formulations for Ipca and the US generics market.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue366 ₹ crore−4.7% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin5.6 %−1.1 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit5.5 ₹ crore—Quarterly, as filedQuarter to Jun 2026Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown.
Return on equity4.68 %−2.4 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin7.45 %+14.2 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)7.15 %−14.0 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

3 of 8 judged targets kept · 3 open · verdicts reflect calls analysed to Q3 FY17.

Unichem Laboratories Limited management guidance track record on Inve: 11 targets tracked across analysed earnings calls (3 achieved, 5 missed, 3 open).

TargetOriginal wordingSaidLatest callVerdict
Domestic Business Growthrobust double-digit growth
Call transcript, Q3 FY16 · 25 Jan 2016		Q3 FY16Q3 FY17:9M FY17 growth clocked in at 'around 12% plus', meeting the double-digit target.
Call transcript, Q3 FY17 · 23 Jan 2017		Achieved
US Business Growth Ratemaintain growth of over 35%
Call transcript, Q3 FY16 · 25 Jan 2016		Q3 FY16Q3 FY17:9M FY17 growth was 23%, which is within the revised 20-30% range but a clear miss on the original 'over 35%' target.
Call transcript, Q3 FY17 · 23 Jan 2017		Missed
Operating Margin Expansion100-150 BPS expansion in the coming year
Call transcript, Q4 FY16 · 23 May 2016		Q4 FY16Q3 FY17:YTD EBITDA margin expansion was only 4 BPS (11.96% vs 11.92% LY). While Q3 YoY showed 133 BPS improvement, the full-year target is at risk.
Call transcript, Q3 FY17 · 23 Jan 2017		At Risk

Source: Inve Guidance Tracker for Unichem Laboratories Limited · to Q3 FY17

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

5 of Unichem Laboratories Limited's 11 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 8 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹481.1 +1.36% · +₹6.45

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +2.6% 1Y

₹300₹400₹500₹600Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26

1Y: ₹469.1 on 24 Oct 2025 → ₹481.1. High ₹650.6 (9 Jul 2026), low ₹284.05 (27 Mar 2026).

Previous close
₹474.65
Market cap
₹3.3k Cr
52-week range
₹284.05 – ₹650.6
One year
+2.34%
Price to earnings (TTM to Jun 2026)
27.62×
Return on equity (TTM to Jun 2026)
4.68%

Overview

Symbol
NSE:UNICHEMLAB
Exchange
NSE
Currency
INR

What Unichem Laboratories Limited does

Based on the company's own presentations, annual report and earnings calls.

Unichem Laboratories Limited is an Indian pharmaceutical manufacturer, incorporated in 1962, that became a subsidiary of Ipca Laboratories Limited. It operates active pharmaceutical ingredient (API) plants at Roha and Kolhapur (Maharashtra) and Pithampur (Madhya Pradesh), and formulation manufacturing facilities at Goa, Ghaziabad, Baddi and Sikkim carrying USFDA, MHRA, ANVISA and TGA approvals. It earns by supplying APIs and formulations to parent Ipca on a contract-manufacturing basis and by selling its own US-market formulations through its wholly-owned US marketing subsidiary, Unichem Pharmaceuticals (USA) Inc., which also markets a portfolio of Ipca-origin, US-ANDA-approved generics. The company previously ran a large India branded-formulations business; that domestic footprint has shrunk sharply since the Ipca ownership change, with the business now weighted toward API/formulation supply and export/US generics.

Segments

  • API (Active Pharmaceutical Ingredients)
  • Formulations
Corporate structure
Subsidiary of Ipca Laboratories Limited, a global pharmaceutical company
API manufacturing plants
Roha and Kolhapur (Maharashtra), Pithampur (Madhya Pradesh)
Formulation manufacturing plants
Goa, Ghaziabad, Baddi (HP) and Sikkim
Plant regulatory approvals
USFDA, MHRA, ANVISA and TGA-approved formulation plants (Goa and Ghaziabad)
US marketing subsidiary
Unichem Pharmaceuticals (USA) Inc., established 2004, markets Unichem-manufactured products in the US
US ANDA product portfolio marketed via Unichem USA
~20 Ipca-origin formulations with approved US ANDAs, ~25 more filings in process
Founded 1962Headquarters Kandivli (West), Mumbai, Maharashtra Company website

Your own record

Start an Inve Case for Unichem Laboratories Limited

Free account: one company. Everything above stays public.

Write why you follow Unichem Laboratories Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Unichem Laboratories Limited

Guides on how to read this kind of business and the numbers that matter.